Revelation Biosciences, Inc. (REVB): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of REVB were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No REVB insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
REVB short interest
Low short interest. 0.3% of REVB shares are sold short: about 1 share in 311. Over the last 12 reports the number of shares short went down 63%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 12,792 REVB shares were sold short, 0.3% of the shares outstanding, up 93.7% from the report before. At the average daily volume of 39,572 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 12,792 | 0.32% | +94% | 39,572 | 1.0 |
| Oct 15, 2026 | 6,605 | 0.17% | +318% | 41,123 | 1.0 |
| Sep 30, 2026 | 1,581 | 0.04% | +518% | 36,220 | 1.0 |
| Sep 15, 2026 | 256 | 0.01% | -56% | 14,833 | 1.0 |
| Aug 31, 2026 | 582 | 0.01% | -96% | 61,763 | 1.0 |
| Aug 14, 2026 | 15,394 | 0.39% | -26% | 21,146 | 1.0 |
| Jul 31, 2026 | 20,729 | 0.53% | +3% | 40,934 | 1.0 |
| Jul 15, 2026 | 20,200 | 0.52% | +45% | 58,166 | 1.0 |
| Jun 30, 2026 | 13,941 | 0.36% | -25% | 38,868 | 1.0 |
| Jun 15, 2026 | 18,630 | 0.48% | -29% | 50,599 | 1.0 |
| May 29, 2026 | 26,240 | 0.67% | -24% | 33,045 | 1.0 |
| May 15, 2026 | 34,510 | 0.88% | +87% | 81,197 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Revelation Biosciences company events
Revelation Biosciences filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Aug 19, 2026LeadershipThe Compensation Committee of the Board of Directors of Revelation Biosciences, Inc. approved grants of restricted shares of the Company’s common stock, including to James Rolke, the Company’s Chief Executive Officer, and Chester S. Zygmont, III, the Company’s Chief Financial Officer, pursuant to… Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 13, 2026AgreementThe Board of Directors of Revelation Biosciences, Inc. adopted a stockholder rights plan and entered into a Rights Agreement with Continental Stock Transfer & Trust Co., as Rights Agent, and declared a dividend of one preferred share purchase right (a “Right”) for each outstanding share of the… Filing
- Jun 24, 2026LeadershipRevelation Biosciences, Inc. entered into an Amended and Restated Executive Employment Agreement with each of James Rolke, the Company’s Chief Executive Officer, and Chester S. Zygmont, III, the Company’s Chief Financial Officer, in each case effective as of June 24, 2026. Filing
- Jun 1, 2026AnnouncementAnd in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of… Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 19, 2026SharesChanged the rights of its shareholders. Filing
- Feb 26, 2026ResultsReleased financial results. Filing
- Jan 29, 2026AgreementRevelation Biosciences, Inc. entered into warrant exercise inducement offer letters with two holders of 8,544,999 (pre-reverse stock split of one-for-four effected on January 28, 2026) existing Class I Common Stock Warrants exercisable for an aggregate of 8,544,999 pre-split (2,136,251 post-split)… Filing
- Jan 22, 2026AnnouncementAnd in Exhibit 99.1 and 99.2 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities… Filing
- Dec 3, 2025AnnouncementAnd in Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Revelation Biosciences financials
Famous investors that hold REVB
1 of the 50 well-known investors we track reported holding REVB in their latest 13F filing. The largest position is Ken Griffin's, worth $81.4K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 118,199 | $81.4K | 0.0% | +158% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Revelation Biosciences, Inc. (REVB) stock
Are REVB insiders buying or selling?
No REVB insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in REVB?
As of Oct 30, 2026, 12,792 REVB shares were sold short, 0.3% of the shares outstanding, up 93.7% from the report before. At the average daily volume of 39,572 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold REVB?
1 of the 50 well-known investors we track reported REVB in their latest 13F filing, including Ken Griffin. The largest position is worth $81.4K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.